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accidental overdose of 2,000,000 IU of vitamin D3
in two nursing home patients: a case report
Jody van den Ouweland1*, Hanneke Fleuren2, Miranda Drabbe3 and Hans Vollaard2Abstract
Background: Administration of intermittent high doses of vitamin D3 is increasingly used as a strategy for rapid
normalization of low 25-hydroxyvitamin D (25(OH)D) blood concentrations in patients with vitamin D deficiency.
Here, we describe the pharmacokinetics of an accidental single oral overdose of 2,000,000 IU of vitamin D3 in two
elderly nursing home patients and discuss safety issues.
Case presentation: Two patients, a Caucasian 90-year old man and a 95-year old woman, were monitored from
1 h up to 3 months after intake for clinical as well as biochemical signs of vitamin D intoxication. Blood vitamin D3
concentrations showed a prompt increase with the highest peak area already hours after the dose, followed by a
rapid decrease to undetectable levels after day 14. Peak blood 25(OH)D3 concentrations were observed 8 days after
intake (527 and 422 nmol/L, respectively (ref: 50–200 nmol/L)). Remarkably, plasma calcium levels increased only slightly
up to 2.68 and 2.73 mmol/L, respectively (ref: 2.20–2.65 mmol/L) between 1 and 14 days after intake, whereas phosphate
and creatinine levels remained within the reference range. No adverse clinical symptoms were noted.
Conclusion: A single massive oral dose of 2,000,000 IU of vitamin D3 does not cause clinically apparent toxicity requiring
hospitalization, with only slightly elevated plasma calcium levels in the first 2 weeks. Toxicity in the long term cannot be
excluded as annual doses of 500,000 IU of vitamin D3 for several years have shown an increase in the risk of fractures.
This means that plasma calcium levels may not be a sensitive measure of vitamin D toxicity in the long term in the case
of a single high overdose. To prevent a similar error in the future, the use of multiple-dose bottles need to be replaced
by smaller single-unit dose formulations.
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Vitamin D deficiency is a highly prevalent condition,
present in approximately 30–50% of the general population
[1], and may be as high as 100% in institutionalized elderly
patients [2,3]. Vitamin D supplementation is increasingly
advised, but compliance with daily dosing regimens is low
[4]. Because serum 25-hydroxyvitamin D3 (25(OH)D3), the
functional indicator of vitamin D status, has a long half-life
of about 2 months [5], there is great interest in intermittent
dosing for patient convenience and long-term adherence.
Administration of 100,000 IU of cholecalciferol (vitamin D3)
every 4 months for 5 years showed a 22% reduction* Correspondence: j.v.d.ouweland@cwz.nl
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article, unless otherwise stated.in the risk of osteoporotic fractures [6], similar to studies
using a daily dose of 800 IU [7]. On the contrary, rapid
increases in serum 25(OH)D from intermittent high doses
of 500,000 IU of vitamin D3 once a year for 3–5 years in
older women, have been shown to increase the risk of falls
and fractures by 26% compared with the use of a placebo
[8]. In clinical studies using high-dose regimens of up to
600,000 IU of vitamin D3, there has been surprisingly little
concern for vitamin D toxicity. Plasma calcium and
urinary calcium excretion both are recognized markers of
vitamin D toxicity [5]. In the few clinical studies that have
analyzed plasma calcium levels and/or urinary calcium
excretion within a month after dosing, calcium levels were
found to be unchanged or only slightly elevated within the
reference range following a loading dose of 300,000 IU [9],
500,000 IU [10], 540,000 IU [11], or 600,000 IU [12,13].Med Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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overdosing by 2,000,000 IU vitamin D3 in two elderly
nursing home patients and discuss safety issues from
single massive oral doses of vitamin D3.
Case presentation
In Waelwick, a nursing home near Nijmegen, all residents
receive osteoporosis prophylaxis with oral vitamin D3
doses of 100,000 IU three times a year as a lyophilized
solution (2 mL vitamin D3 aquosum FNA, 50,000 IU/mL).
Two nursing home patients each received an accidental
single overdose of 2,000,000 IU vitamin D from a whole
bottle of a concentrated vitamin D3 solution (40 mL vitamin
D3 aquosum FNA 50,000 IU/mL). The pharmacy depart-
ment was surprised by the order for 25 new bottles imme-



























































Figure 1 Time course of plasma calcidiol and calcium concentrations,
(cholecalciferol), after a single oral dose of 2,000,000 IU of vitamin D
calcium measurements that show a biologically significant difference from
vitamin D3 (cholecalciferol) and the upper plots.lasted for half of a year of treatment for the patients at the
ward. It then became clear that an overdose had been given.
For safety reasons, we immediately started biochemical and
clinical monitoring of both patients. Plasma calcium, phos-
phate, creatinine, and 25(OH)D levels were measured from
1 h after dosing up to 106 days (case 1) and 71 days (case 2)
(Figure 1, Table 1). Vitamin D3 was measured at time points
1 h, 0.5, 1, 2, 8, and 14 days after dosing (Figure 1). Because
of the nature of this study, baseline concentrations
(prior to dosing) were lacking. Unfortunately, we lacked
the opportunity for measuring 1,25-dihydroxyvitamin D
and 24,25-dihydroxyvitamin D (because of limited avail-
ability of plasma material), parathyroid hormone (PTH)
and bone turnover markers (lack of the appropriate blood
containers or pre-analytical conditions), and urinary calcium



























































as well as semi-quantitative measurements of plasma vitamin D3
to two nursing home residents. The asterisk indicates the individual
baseline concentrations. Note the time-scale differences between the
Table 1 Biochemical values from single high-dose vitamin D3 administration in two cases
Reference range 1 h 5.5 h 1d 2d 3d 4d 8d 11d 14d 22d 29d 36d 43d 60d 71d 106d
Case 1
Calcidiol (nmol/L) 50-200 59 224 395 448 527 522 403 323 318 283 203 131
Calcium (mmol/L) 2.20-2.65 2.52 2.51 2.57 2.64 2.67 2.64 2.68 2.63 2.57 2.45 2.5 2.5 2.43 2.43
Phosphate (mmol/L) 0.80-1.40 1.08 1.09 1.05 1.30 1.13 1.14 1.37 1.32 1.01 1.00 0.98 0.97 0.96
Creatinine (μmol/L) 60-110 64 65 66 68 69 73 69 77 75 71 69 63 66 75 65
Case 2
Calcidiol (nmol/L) 50-200 77 326 354 422 405 363 322 324 255 233
Calcium (mmol/L) 2.20-2.65 2.46 2.69 2.73 2.68 2.69 2.66 2.70 2.57 2.59 2.50 2.49 2.59 2.57
Phosphate (mmol/L) 0.80-1.40 0.91 1.20 1.06 1.12 1.05 1.13 1.02 1.07 0.82 0.82 0.89 0.87 0.79
Creatinine (μmol/L) 50-90 45 51 44 55 54 52 52 49 52 41 50 54 45
Values outside the reference range are indicated in bold. h, hours; d, days. Conversion factors: calcidiol (mg/dL = 0.4 ×mmol/L), calcium (mg/dL = 4 ×mmol/L),
phosphate (mg/dL = 3.1 ×mmol/L), creatinine (mg/dL = 0.01 × μmol/L).
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well as semi-quantitative measurement of vitamin D3
(monitoring peak area), were performed using liquid
chromatography-tandem mass spectrometry as previously
described [14]. Plasma calcium, phosphate, and cre-
atinine levels were measured on a routine clinical
chemistry analyzer (Modular; Roche Diagnostics, Mannheim,
Germany). Changes of biological significance were
calculated from reference change (RCV, at a 95% confi-
dence interval) according to the formula RCV = Z × 21/2
ðCV2a þCV2aÞ 1/2 [15], where Z = 1.96 (i.e., the Z-score
for 95% confidence), CVa = analytical variation, and
CVi = intra-individual variation. For calcium, CVa and
CVi were 1.5% and 1.9%, respectively [16].
Case 1 was a 90-year-old man of Caucasian origin,
with normal kidney function (estimated glomerular
filtration rate by Modification of Diet in Renal Disease
(MDRD) equation >60 mL/min), and an absence of
significant pathology. He did not report any clinical signs
or symptoms of vitamin D toxicity. His plasma calcium
was 2.52 mmol/L 1 h after dosing and showed a
non-significant increase from day 1 to day 8, with a
maximum of 2.68 mmol/L at day 8. After 8 days,
plasma calcium levels fell to within the reference
range (2.2–2.65 mmol/L) (Figure 1). At first measurement,
1 h after gift, vitamin D3 was already detected. The
vitamin D3 peak area showed a prompt increase with
the highest peak area already at the second measurement,
5.5 h after dosing, followed by a rapid decrease to
undetectable levels at day 14. Plasma 25(OH)D3 con-
centrations also were already markedly increased 5.5 h
after dosing, but rose more slowly than vitamin D3,
reaching a maximum of 527 nmol/L at day 8. Over
the following 3-month period, 25(OH)D3 concentrations
decreased by 50% over an approximately 50-day period.
At the end of the 106-day follow-up period, the patient’s
25(OH)D3 concentration was 113 nmol/L and fell within
the laboratory reference range (50–200 nmol/L). Plasma
phosphate and creatinine levels showed a modest increase
within the reference range (Table 1).Case 2 relates to a 95-year-old woman of Caucasian
origin, with normal kidney function (MDRD >60 mL/min)
and an absence of significant pathology. She did not report
any clinical signs or symptoms of vitamin D toxicity. Her
plasma calcium was 2.46 mmol/L 1 h after dosing and
showed a biologically significant increase from day 1 to day
11 with a maximum of 2.73 mmol/L at the second day.
After 11 days, plasma calcium levels dropped to within the
reference range of 2.2–2.65 mmol/L (Figure 1). Vitamin D3
peak area was highest at the first measurement opportun-
ity, being 1-day post-dose, followed by a rapid decrease to
undetectable levels after day 14. Plasma 25(OH)D3 concen-
trations also were already markedly increased 1 day after
dosing, but rose more slowly than vitamin D3, reaching a
maximum of 422 nmol/L at day 8. At the end of the
71-day follow-up period, the 25(OH)D3 concentration
was 233 nmol/L, with an approximate 50% decrease
from the highest level being still above the upper normal
limit of 200 nmol/L. Plasma phosphate and creatinine
levels both showed a modest increase within the reference
range (Table 1).
Discussion
Pharmacokinetic studies in human volunteers given a
single large oral dose of 100,000 IU of vitamin D3 indicate
that serum vitamin D3 and 25(OH)D3 levels peak on days 1
and 7, respectively [17,18]. The vitamin D3 concentrations
fell rapidly, being close to baseline by day 7, with a much
slower fall of the 25(OH)D3 concentrations. Plasma calcium
levels did not rise at any time, and no subject experienced
hypercalcemia at any of the measured time points [17]. The
pharmacokinetic profiles of our two cases resembled those
from the 100,000 IU study and emphasize the importance
of measuring 25(OH)D and calcium concentrations over
the first 14 days for identifying the maximum blood
concentrations. The half-life of the plasma 25(OH)D
levels of about 50 days in case 1 is comparable to a
half-life of about 2 months as described previously [5]. The
relatively normal 25(OH)D3 concentrations in our nursing
home residents (59 nmol/L in case 1 and 77 nmol/L in case
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explained as the result of previous osteoporosis
prophylaxis treatments with 100,000 IU of oral vitamin D3.
However, we cannot exclude the possibility that the plasma
25(OH)D concentrations were already increased 1 h
after the high dose of vitamin D3, implicating that the
baseline 25(OH)D values in both cases actually may
have been lower.
The toxicity of vitamin D in daily administration has been
studied extensively. The present view is that hypercalcemia
is the hazard criterion for vitamin D [19]. Thus, vitamin D
toxicity is supposed to be inseparable from hypercalcemia.
Hypercalcemia does not occur with daily doses up to
40,000 IU of vitamin D3 and serum levels of 25(OH)D3 up
to 500 nmol/L, well above naturally occurring levels
of 25(OH)D3 [20]. Most patients with an overdose of
vitamin D3 are not seen by a physician until they are
admitted to the emergency department with clinical
signs of intoxication, such as life-threatening dehydration,
after a prolonged period of oral intake of high-dose
vitamin D, either from contaminated food components
[21,22] or supplements with errors in manufacturing
and/or labeling [23,24].
Much less is known about the toxicity of vitamin D3
following a single high oral dose of vitamin D3. In studies
using 300,000 IU [9], 540,000 IU [11], and 600,000 IU
[12,13] of oral vitamin D3, no adverse effects were noted
and plasma calcium levels or urinary calcium excretion did
not change, or only slightly increased for a short period of
time, with all cases remaining within the physiological
range. In contrast to these reassuring data, Sanders et al.
[8] found a significant increase in the risk of falls (+15%)
and fractures (+26%) in a randomized controlled trial with
an annual dose of 500,000 IU vitamin D3 for 3–5 years in
older women compared with placebo. Falls and fractures
occurred especially within the first 3 months following the
annual dose of vitamin D3. In that study, plasma calcium
levels and urinary calcium excretion were not measured;
however, bearing in mind the former data, it is unlikely that
hypercalcemia occurred in the study. These unexpected
findings led Rossini et al. [13,25] to investigate dose-
dependent short-term effects on bone turnover markers of
a single bolus of vitamin D3. A single dose of 600,000 IU of
vitamin D3 increased serum C-terminal telopeptide
of type 1 collagen and cross-linked N-telopeptide of
type 1 collagen significantly at day 1, attained a peak
increment greater than 50% at day 3, and subsequently
decreased almost back to baseline values at day 90, with-
out statistically significant changes in plasma calcium [13].
Their results indicate that the use of oral megadoses
greater than 100,000 IU of vitamin D may be counterpro-
ductive and that the safety issues surrounding vitamin D
dosing should not be limited to early markers of
vitamin D toxicity as plasma hypercalcemia or increasedurinary calcium excretion [13,25]. A possible explanation
is the fact that the level of 1,25 dihydroxy-vitamin D is
regulated much stronger in the endocrine system than
in the autocrine system of vitamin D [5]. If the
plasma level of calcidiol (the substrate of the autocrine
vitamin D system) increases sharply after a loading dose
that deviates too much from the maximum physiological
daily dose with sunlight (20,000 IU), this might result
in toxic intracellular calcitriol levels in the autocrine
vitamin D system without toxic circulating calcitriol
levels in the endocrine system of vitamin D and without
hypercalcemia. If that is the case, we need other markers
than hypercalcemia to prove vitamin D toxicity in
the autocrine system, such as bone turnover markers
[13]. In any case, more studies are needed to evaluate
potential adverse effects of high-dose vitamin D treat-
ment on bone metabolism in relation to fracture risk
and risk of falls.
The present study displays some limitations. We lacked
the opportunity for studying other relevant parameters in
the risk assessment for vitamin D3, such as measurement
of urinary calcium excretion and plasma levels of
1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, PTH,
and bone turnover markers. Because of the nature of
this study, baseline concentrations (prior to dosing) of
biochemical parameters such as plasma vitamin D3,
25(OH)D, and calcium were lacking.Conclusion
In our two patients, the massive single overdose of
2,000,000 IU of vitamin D3 did not result in immediate
clinical and biochemical toxicity requiring hospitalization,
with only slightly elevated plasma calcium levels in the
first 2 weeks. However, toxicity in the long term cannot be
excluded as an annual dose of 500,000 IU of vitamin D3
for several years has shown an increased risk of fractures.
This may implicate that markers other than plasma
calcium measurement, such as bone turnover markers,
are needed to assess the safety of high doses of vitamin D
in the long term. Clearly, the safety of high-dose vitamin
D supplementation warrants further study. To prevent a
similar error in the future, the use of multiple-dose bottles
were replaced by smaller single-unit dose formulations of
25.000 IU/mL. In general, we believe that available formu-
lations of vitamin D3 should not exceed 100,000 IU, as
long as the safety of high doses of vitamin D in the long
term has not been established.Consent
Written informed consent for publication of their clinical
details was obtained from the relatives of both patients. A
copy of the written consent is available for review by the
Editor of this journal.
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